2026· American Journal of Cancer Research· Vol 16 8, pp.
3359-3376
· 0 citations
Medicine
TL;DR
It is demonstrated that serum exosomal miR-17-3p is a promising biomarker for GC diagnosis and evaluation and validated candidate miRNAs using quantitative real-time PCR.
Abstract
Early detection of gastric cancer (GC) improves patient outcomes. However, conventional serum biomarkers show limited sensitivity in early disease stages. Circulating microRNAs (miRNAs) are remarkably stable in body fluids. These molecules have emerged as promising noninvasive biomarkers. In this study, we isolated serum-derived exosomes from healthy controls and GC patients. Transmission electron microscopy, nanoparticle tracking analysis, and Western blotting confirmed exosomal characteristics. Small RNA sequencing then established miRNA expression profiles to identify progression-associated molecules. We conducted bioinformatics analyses to explore their biological roles and validated candidate miRNAs using quantitative real-time PCR. Notably, miR-17-3p levels declined progressively during disease development. This expression level correlated significantly with tumor differentiation (P = 0.0324), TNM stage (P = 0.0100), and neural invasion (P = 0.0100). Combining miR-17-3p with conventional markers increased the area under the curve (AUC) from 0.7847 to 0.8472 for staging. These findings demonstrate that serum exosomal miR-17-3p is a promising biomarker for GC diagnosis and evaluation.
The miR-6838-5p/miR-195-5p combination represents a promising circulating miRNA signature for invasive ductal breast carcinoma and its consistent discriminatory performance in the discovery cohort and an independent serum cohort supports further evaluation in larger prospective studies.
Mustafa Barış Zeytunlu, Fazilet Esra Incedere Duzdag, Hüseyin Esin et al.· Molecular Biology Reports· 0 citations
Breast carcinoma remains the most frequently diagnosed malignancy among women globally, carrying a substantial burden of incidence and fatality. Timely diagnosis and intervention are of utmost significance for improving patient prognosis. Accumulating evidence suggests that microRNAs (miRNAs) derived from plasma exosom...
Guang-Fu Pang, Sheng-Shan Yuan, Chen Yang et al.· Journal of Visualized Experi...· 0 citations
microRNAs (miRNAs) are emerging as promising biomarkers in hematological malignancies due to their stability in blood. This study aimed to investigate the differential expression of miRNAs in chronic myeloid leukemia (CML) and evaluate the potential of miR-451a as a candidate whole-blood miRNA marker.
We c...
Surbhi Gupta, Nitu Nigam, Abdullah H. Maad et al.· BMC Cancer· 0 citations
Purpose Advanced renal cell carcinoma (RCC) has a poor prognosis due to metastasis, delayed diagnosis and drug resistance. Therefore, the early diagnosis of the disease is of vital importance, but currently there are no validated circulating blood biomarkers available for the prediction of early-stage renal cell carcin...
Yu Sun, Zhi-Cheng Li, Chao Ren et al.· Frontiers in Oncology· 0 citations
The combination of miR-210, miR-21, miR-155, and miR-122 represents a promising, noninvasive diagnostic panel for renal cell carcinoma that discriminates RCC patients — including those with advanced-stage disease — from individuals with benign kidney disease and healthy individuals in an Iraqi cohort.
Maytham Khazaal Kadhim· BIO Web of Conferences· 0 citations
Abstract Introduction: Breast cancer (BC) remains a leading cause of cancer-related mortality among women worldwide. Despite advances in molecular diagnostics, reliable non-invasive biomarkers for early detection and disease staging remain limited. Circulating microRNAs (miRNAs) are promising epigenetic regulators invo...
A. Abdel-Hamed, Marina Barsom, Mahmoud M. Kamel et al.· Journal of Circulating Bioma...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.